TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03973177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenol Injection
Description: 6% aqueous phenol 2.5 mL will be mixed with 0.5 mL iopamidol 300 and will be injected at each target site with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged phenol covering the lateral margin of the femur or tibia respectively on AP and lateral views. The needles will then be removed and band-aids placed.

Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone Injection
Description: Methylprednisolone acetate 10 mg with 2 mL preservative saline and 0.5 mL iopamidol 300 will be injected at each of the 3 target sites with live, pulsed fluoroscopy (5-8 seconds at each location) to observe the contrast dye-tagged steroid mixture covering the lateral margin of the femur or tibia respectively on AP and lateral views; the needles will be removed and band-aids placed.
Study: NCT02996656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: Antibiotic that will be give before a Trauma or elective open shoulder surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Antibiotic that will be give before a Trauma or elective open shoulder surgery
Study: NCT01203878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Administered 4 weeks after completion of imiquimod therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
Study: NCT02769637

Intervention type: DRUG
Intervention: PPI treatment
Description: PPI treatment or no PPI treatment
Study: NCT01498848

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cooking oils
Description: Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cooking oils
Description: Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
Study: NCT03883906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viral Specific T-cells (VSTs)
Description: VSTs will be infused into stem cell transplant recipients
Study: NCT04219566

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VeNS
Description: Non-invasive electrical vestibular nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo device
Description: Sham non-invasive electrical vestibular nerve stimulation
Study: NCT01001845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Thistle extract
Description: 1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vit E
Description: 200 mg twice daily for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vit E + Milk Thistle extract
Description: 200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
Study: NCT03124966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Oximeter sensor
Study: NCT00002725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study: NCT02274129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healing cap II
Description: Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
Study: NCT02188641

Intervention type: OTHER
Group type: OTHER
Intervention: Diet

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Diet and Exercise

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Lifestyle (Control) Group
Study: NCT02837757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological samples
Description: blood and tumor tissue samples
Study: NCT06176287

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implantation with high torque
Description: Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with high insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Implantation with low torque
Description: Fifteen patients with bilateral single-tooth loss in the posterior mandible will be included in the study. One implant was randomly placed with low insertion torque in each patient. A total of 15 implants will be placed, and insertion torque values will be recorded.
Study: NCT03119935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amflow
Description: Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu bag
Description: Participants ventilated the simulated patients by ambu bag
Study: NCT02441478

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: functional magnetic resonance imaging exam

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging exam
Study: NCT03615300

Intervention type: DIAGNOSTIC_TEST
Intervention: serum NGAL
Description: serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.

Intervention type: DIAGNOSTIC_TEST
Intervention: serum NGAL
Description: serum NGAL was measured at 0, 24, 48, and 72 hours after recovery of spontaneous circulation.
Study: NCT03006419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: Standard induction therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Induction therapy
Study: NCT03486990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIMP-GLIA
Description: intravenous infusion.
Study: NCT01221376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
Study: NCT01735630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELND005

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02463695

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cortical vestibular evoked potentials (CVEPs)
Description: CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cortical vestibular evoked potentials (CVEPs)
Description: CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
Study: NCT00795015

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin regular IV infusion
Description: IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin regular IV infusion
Description: IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV insulin infusion
Description: IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV insulin infusion
Description: IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
Study: NCT01288131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine combine with mycophenolate mofetil
Description: Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide + pred
Description: Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day
Study: NCT04055337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flap sliding
Description: All subjects underwent the flap sliding technique, which was performed at the Alforsan Eye Centre in Assiut, Egypt. Prior to surgery, all subjects underwent corneal imaging with anterior segment optical coherence tomography to confirm the presence of striae. All surgical procedures were performed by the same surgeon 1 or 2 days following LASIK.~Subjects were administered a topical anesthetic. Striae location and orientation were then determined after drying the corneal surface with a cellulose sponge. The sponge was used to push the LASIK flap over the stromal bed in a direction that was perpendicular to the striae. The flap was pushed from the proximal side of the striae toward the flap edge. The ultimate goal was to move striae and put the flap into its proper place. Following surgery, OCT imaging was repeated.
Study: NCT01396278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching fluticasone propionate HFA MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate HFA MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Fluticasone propionate HFA MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903 via Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903 via Respimat inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 54903
Description: BI 54903 via Respimat inhaler
Study: NCT02195245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: memsorb
Study: NCT04910126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg q3w up to 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adriamycin
Description: adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: adriamycin 20mg/m2 d1-3 q3w maximum 6 cycles
Study: NCT02244034

Intervention type: PROCEDURE
Intervention: hypothermia
Study: NCT04227639

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece trial
Description: T-piece trial will be performed for around 1 hour with a T-piece connected to the extremity of the endotracheal tube by simply disconnecting the patient from the ventilator and by providing additional oxygen (≤ 6 L/min)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure-support trial
Description: Pressure-Support trial will be performed for around 1 hour without disconnecting the patient from the ventilator, by using a low level of pressure-support (PS 8 cm H2O) with a FiO2 ≤ 40% and without positive end-expiratory pressure (PEEP), while continuously monitoring the respiratory rate and tidal volume on the ventilator display.
Study: NCT03203447

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: suprachoroidal CLS-TA
Description: suprachoroidal injection of CLS-TA

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: suprachoroidal sham
Description: sham suprachoroidal procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis or Avastin
Description: IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lucentis or Avastin
Description: IVT anti-VEGF agent. Either a 0.5 mg intravitreal injection of Lucentis or 1.25 mg intravitreal injection of Avastin
Study: NCT03311152

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)
Description: The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)
Description: The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
Study: NCT03884543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized high PEEP strategy
Description: Patients are randomized and intra-operatively ventilated with an individualized high PEEP strategy (Highest PEEP with the lowest driving pressure with recruitment maneuvers)
Study: NCT04513912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Participants will receive seltorexant over-encapsulated tablet orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to Seltorexant
Description: Participants will receive placebo over-encapsulated tablet matching to seltorexant orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: Participants will receive quetiapine XR capsule orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo to Quetiapine XR
Description: Participants will receive placebo capsule matching to quetiapine XR orally.
Study: NCT01705769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food-Centrally produced
Description: Ready to Use Therapeutic Food-Centrally produced by an Indian company.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ready to Use Therapeutic Food-Locally produced
Description: Ready to Use Therapeutic Food prepared by the study team

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High energy and micronutrient rich foods
Description: High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
Study: NCT03117569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glecaprevir (300mg)/pibrentasvir (120mg)
Description: glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: glecaprevir (300mg)/pibrentasvir (120mg)
Description: glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
Study: NCT01118247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uncemented primary total hip arthroplasty
Description: Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented primary total hip arthroplasty
Description: Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
Study: NCT01449630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3031207
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally
Study: NCT01876706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroLift® System
Description: The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
Study: NCT01390337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC220
Description: Oral Liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Intravenous Infusion
Study: NCT01709474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 6000 IU
Description: Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing \<40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 400 IU
Description: Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
Study: NCT01244126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal fentanyl
Description: 2mcg/kg fentanyl IN

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine IM
Description: 0.1 mg/kg morphine IM for postop pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine
Description: 0.1 mg/kg morphine IV
Study: NCT03713281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric Multifocal etafilcon A with PVP
Description: Investigational
Study: NCT02749513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study: NCT02366780

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pump
Description: Breast milk expression using manually or using an electric pump

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pump
Description: Breast milk expression using manually or using an electric pump
Study: NCT01716793

Intervention type: DRUG
Group type: OTHER
Intervention: Ara-C
Description: * Intermediate dose during induction phase to remission.~* High-dose during consolidation phase in patients with favorable cytogenetics.

Intervention type: OTHER
Group type: OTHER
Intervention: Autologous transplantation
Description: * In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.~* In patients with other cytogenetics without HLA-Identical sibling.

Intervention type: OTHER
Group type: OTHER
Intervention: Allogeneic HLA-identical sibling transplantation
Description: * Patients without favorable or normal karyotype(and one course to CR).~* Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics.

Intervention type: OTHER
Group type: OTHER
Intervention: CD34+ selection
Description: In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
Study: NCT04448223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-351
Description: Latanoprost (25ug/ml), Dorzolamide (20mg/ml), twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost+Dorzolmamide
Description: Latanoprost(50ug/ml) , once a day Dorzolmamide(20mg/ml), threetimes a day
Study: NCT03746093

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Participants will consume a bottle of water (330 ml) every day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Non-alcoholic beer
Description: Participants will consume non-alcoholic beer (330 ml) every day for 12 weeks.
Study: NCT02109042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blosozumab
Description: Administered subcutaneously
Study: NCT00822874

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prematuration culture
Description: The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos.
Study: NCT00765648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicardipine intravenous
Description: nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
Study: NCT02401386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Eight Brocades
Description: Patients received closely supervised, group-format EB program and practiced EB revised by Chinese Medicine Master Zhi-zheng Lu for one hour, twice weekly for 12 weeksmovements, a review of principles, and breathing techniques in EB. Participants will be asked to practice EB at home for at least 16 minutes each day which is how long it takes to complete an EB exercise, using an instructional Digital Video Disc. The program will be taught by experienced EB masters.
Study: NCT00740493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: warfarin
Description: 18 months of warfarin therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo of warfarin
Description: 18 months of placebo of warfarin therapy